2017 to Baht 1,842 million in 2018, primarily due to commercial operation of new plants and an improvement on financing cost mainly attributable to debt refinancing after issuing project bond in May 2018
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
5.55 420.91 5.95 249.78 3.74 Trade and other current receivables 798.97 11.07 728.84 10.31 623.81 9.33 Other short-term loans 21.53 0.30 41.55 0.59 51.55 0.77 Inventories 1,302.01 18.04 1,109.49 15.70
(728.0) Current investment - 4,046.1 (4,046.1) Trade and other receivables 1,186.5 1,535.4 (348.9) Reimbursable maintenance expense 955.6 857.8 97.8 Other current financial assets 2,936.1 - 2,936.1 Other
, decreased by Baht 5.0 million or 9.9% compared to Q3/2019. The decrease was mainly due to loans repayment during Q4/2019. The interest-bearing debt at the end of Q4/2019 was Baht 4,685.9 million, reduced from
than previous assessment at 4.0%. Moreover, the growth outlook still challenge with uncertainties from both domestic and external factors due primarily to 1) Trade protectionist measures between US and
License return shall reduce debt burdens of 7.1 the Company; enabling it to repay debts to creditors and continuously run the businesses. At present, the Company has liabilities with interest with financial
management, e. g. , deposit with financial institutions, investment in debt instruments, the Company will earn a relatively lower rate of return. Therefore, it was deemed appropriate to change the purposes of
,Samutsakhon 74000,Thailand. amounted to THB 637.24 Million as of June 30, 2018. If such balance is invested for liquidity management, e. g. , deposit with financial institutions, investment in debt instruments